GlaxoSmithKline plc (LON:GSK) had its target price boosted by Jefferies Group LLC from GBX 1,675 ($22.26) to GBX 1,700 ($22.59) in a report released on Monday morning. Jefferies Group LLC currently has a buy rating on the stock.

Several other equities analysts also recently commented on the stock. Deutsche Bank AG set a GBX 1,610 ($21.39) target price on shares of GlaxoSmithKline plc and gave the stock a neutral rating in a report on Thursday, October 12th. UBS AG set a GBX 1,550 ($20.60) target price on shares of GlaxoSmithKline plc and gave the stock a neutral rating in a report on Tuesday, October 10th. Liberum Capital lowered their target price on shares of GlaxoSmithKline plc from GBX 1,900 ($25.25) to GBX 1,760 ($23.39) and set a buy rating on the stock in a report on Wednesday, October 4th. J P Morgan Chase & Co reaffirmed a neutral rating and set a GBX 1,570 ($20.86) price target on shares of GlaxoSmithKline plc in a research note on Monday, October 2nd. Finally, Shore Capital reaffirmed a hold rating on shares of GlaxoSmithKline plc in a research note on Wednesday, September 20th. Four equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and seven have assigned a buy rating to the company. GlaxoSmithKline plc currently has a consensus rating of Hold and an average price target of GBX 1,683.50 ($22.37).

Shares of GlaxoSmithKline plc (LON GSK) opened at 1536.00 on Monday. The stock’s 50 day moving average is GBX 1,501.97 and its 200 day moving average is GBX 1,580.88. The stock’s market cap is GBX 75.08 billion. GlaxoSmithKline plc has a 52-week low of GBX 1,444.00 and a 52-week high of GBX 1,724.50.

COPYRIGHT VIOLATION WARNING: This report was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/10/20/jefferies-group-llc-raises-glaxosmithkline-plc-gsk-price-target-to-gbx-1700.html.

The business also recently declared a dividend, which was paid on Thursday, October 12th. Stockholders of record on Thursday, August 10th were issued a GBX 19 ($0.25) dividend. This represents a dividend yield of 1.23%. The ex-dividend date was Thursday, August 10th.

In related news, insider Simon Dingemans purchased 1,076 shares of the business’s stock in a transaction dated Thursday, October 12th. The shares were purchased at an average cost of GBX 1,527 ($20.29) per share, for a total transaction of £16,430.52 ($21,831.68). Also, insider Manvinder Singh Banga purchased 2,267 shares of the business’s stock in a transaction dated Wednesday, July 26th. The stock was bought at an average price of GBX 1,599 ($21.25) per share, for a total transaction of £36,249.33 ($48,165.47). Over the last 90 days, insiders bought 3,368 shares of company stock worth $5,305,807.

About GlaxoSmithKline plc

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline plc (LON:GSK)

Receive News & Stock Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related stocks with our FREE daily email newsletter.